Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy

Trial Profile

Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2018

At a glance

  • Drugs Sufentanil (Primary)
  • Indications Postoperative pain
  • Focus Registrational; Therapeutic Use
  • Sponsors AcelRx Pharmaceuticals
  • Most Recent Events

    • 02 Nov 2018 According to an AcelRx Pharmaceuticals media release, U.S. Food and Drug Administration has approved DSUVIA for the management of acute pain in adults that is severe enough to require an opioid analgesic in certified medically supervised healthcare settings, such as hospitals, surgical centers, and emergency departments.
    • 15 Oct 2018 According to an AcelRx Pharmaceuticals media release, data will be presented at the American Society of Anesthesiologists (ASA).
    • 12 Oct 2018 According to an AcelRx Pharmaceuticals media release, the Anesthetic and Analgesic Drug Products Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 10-3 in favour of recommending the approval of DSUVIA for the management of moderate-to-severe acute pain in medically supervised settings for adult patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top